Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16895681 | 1.00 | USP30 (0.50) | USP30PARP1EPHX1BRD4BTK | |
| SCHEMBL16895680 | 1.00 | USP30 (0.50) | USP30PARP1EPHX1BRD4BTK | |
| SCHEMBL16895918 | 0.88 | USP30 (0.49) | USP30PARP1EPHX1BRD4BTK | |
| SCHEMBL16791247 | 0.88 | USP30 (0.49) | USP30PARP1EPHX1BRD4BTK | |
| SCHEMBL22605914 | 0.87 | ALDH1A1 (0.55) | PARP1EPHX1BTKIDH1ALDH1A1 | |
| SCHEMBL26679982 | 0.86 | USP30 (0.49) | USP30PARP1EPHX1BRD4BTK | |
| SCHEMBL16901718 | 0.85 | MEN1 (0.46) | USP30PARP1EPHX1BTKFPR3 | |
| SCHEMBL25431747 | 0.84 | POLB (0.46) | EPHX1ALDH1A1POLB | |
| SCHEMBL25431751 | 0.84 | POLB (0.46) | EPHX1ALDH1A1POLB | |
| SCHEMBL16895884 | 0.84 | USP30 (0.47) | USP30PARP1EPHX1BRD4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4225288-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225309-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022081478-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022076589-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | USP30 809/4885PARP1 1002/4885EPHX1 1592/4885 |
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | USP30 809/4885PARP1 1002/4885EPHX1 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.